Cormorant Asset Management’s MoonLake Immunotherapeutics MLTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $401M | Hold |
8,494,151
| – | – | 29.86% | 1 |
|
|
2025
Q1 | $332M | Hold |
8,494,151
| – | – | 24.95% | 1 |
|
|
2024
Q4 | $460M | Hold |
8,494,151
| – | – | 25.26% | 1 |
|
|
2024
Q3 | $428M | Hold |
8,494,151
| – | – | 22.71% | 1 |
|
|
2024
Q2 | $373M | Hold |
8,494,151
| – | – | 21.58% | 1 |
|
|
2024
Q1 | $427M | Hold |
8,494,151
| – | – | 18.72% | 1 |
|
|
2023
Q4 | $513M | Buy |
8,494,151
+352,051
| +4% | +$21.3M | 24.5% | 1 |
|
|
2023
Q3 | $464M | Hold |
8,142,100
| – | – | 27.07% | 1 |
|
|
2023
Q2 | $415M | Buy |
8,142,100
+1,249,999
| +18% | +$63.7M | 23.26% | 1 |
|
|
2023
Q1 | $147M | Buy |
6,892,101
+827,100
| +14% | +$17.7M | 9.71% | 2 |
|
|
2022
Q4 | $63.7M | Hold |
6,065,001
| – | – | 4.26% | 4 |
|
|
2022
Q3 | $47.1M | Hold |
6,065,001
| – | – | 3.29% | 6 |
|
|
2022
Q2 | $30.9M | Buy |
6,065,001
+2,785,001
| +85% | +$14.2M | 2.34% | 10 |
|
|
2022
Q1 | $33.3M | Buy |
3,280,000
+2,850,000
| +663% | +$28.9M | 2.55% | 14 |
|
|
2021
Q4 | $4.25M | Hold |
430,000
| – | – | 0.25% | 57 |
|
|
2021
Q3 | $4.28M | Hold |
430,000
| – | – | 0.17% | 72 |
|
|
2021
Q2 | $4.45M | Hold |
430,000
| – | – | 0.15% | 80 |
|
|
2021
Q1 | $4.39M | Hold |
430,000
| – | – | 0.1% | 93 |
|
|
2020
Q4 | $4.74M | Buy |
+430,000
| New | +$4.74M | 0.11% | 82 |
|